Stock Research for PTX

Featured Broker: Ally Invest

Get the due diligence for another stock.


PTX Stock Chart & Research Data

The PTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


PTX Due diligence Resources & Stock Charts

The PTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PTX Detailed Price Forecast - CNN Money CNN View PTX Detailed Summary - Google Finance
Yahoo View PTX Detailed Summary - Yahoo! Finance Zacks View PTX Stock Research & Analysis -

Stock Analysis

TradeIdeas View PTX Trends & Analysis - Trade-Ideas Barrons View PTX Major Holders - Barrons
NASDAQ View PTX Call Transcripts - NASDAQ Seeking View PTX Breaking News & Analysis - Seeking Alpha
Spotlight View PTX Annual Report - OTC Report View PTX OTC Short Report -
TradeKing View PTX Fundamentals - TradeKing Charts View PTX SEC Filings - Bar Chart
WSJ View Historical Prices for PTX - The WSJ Morningstar View Performance/Total Return for PTX - Morningstar
MarketWatch View the Analyst Estimates for PTX - MarketWatch CNBC View the Earnings History for PTX - CNBC
StockMarketWatch View the PTX Earnings - StockMarketWatch MacroAxis View PTX Buy or Sell Recommendations - MacroAxis
Bullish View the PTX Bullish Patterns - American Bulls Short Pains View PTX Short Pain Metrics -

Social Media Mentions

StockTwits View PTX Stock Mentions - StockTwits PennyStocks View PTX Stock Mentions - PennyStockTweets
Twitter View PTX Stock Mentions - Twitter Invest Hub View PTX Investment Forum News - Investor Hub
Yahoo View PTX Stock Mentions - Yahoo! Message Board Seeking Alpha View PTX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for PTX - Insider Cow View Insider Transactions for PTX - Insider Cow
CNBC View PTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PTX - OTC Markets
Yahoo View Insider Transactions for PTX - Yahoo! Finance NASDAQ View Institutional Holdings for PTX - NASDAQ

Stock Charts

FinViz View PTX Stock Insight & Charts - StockCharts View PTX Investment Charts -
BarChart View PTX Stock Overview & Charts - BarChart Trading View View PTX User Generated Charts - Trading View

Latest Financial News for PTX

Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss
Posted on Friday June 22, 2018

Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that Nalpropion Pharmaceuticals, Inc. (“Nalpropion”), the special purpose vehicle (“SPV”) created by Pernix and an investor group (collectively with Pernix, the “Investors”), has been informed by Orexigen Therapeutics, Inc. (“Orexigen”) that no other bids for Orexigen’s assets were received by the court-approved bid deadline.  Accordingly, Nalpropion anticipates being declared the highest and best bidder for the assets and closing on the transaction by July 13, 2018, subject to satisfaction of the closing conditions, including court approval. In April 2018, Nalpropion entered into a “stalking horse” asset purchase agreement to acquire certain assets of Orexigen, including worldwide rights to Contrave® (naltrexone HCl / bupropion HCl), a prescription-only weight loss medication, for $75 million in cash.

Edited Transcript of PTX earnings conference call or presentation 10-May-18 8:30pm GMT
Posted on Thursday May 17, 2018

Q1 2018 Pernix Therapeutics Holdings Inc Earnings Call

Pernix Therapeutics Reports First Quarter 2018 Financial Results
Posted on Thursday May 10, 2018

MORRISTOWN, N.J., May 10, 2018-- Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced today its financial results for the three months ended March 31, 2018.. First Quarter ...

Should You Worry About Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) CEO Pay Check?
Posted on Wednesday May 02, 2018

John Sedor took the helm as Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) CEO and grew market cap to US$28.02M recently. Understanding how CEOs are incentivised to run and grow their companyRead More...

Enter a stock symbol to view the stock details.